Lesinurad/allopurinol

From Wikipedia, the free encyclopedia
Lesinurad/allopurinol
Combination of
Lesinuradurate transporter inhibitor
Allopurinolxanthine oxidase inhibitor
Clinical data
Trade namesDuzallo
AHFS/Drugs.comProfessional Drug Facts
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Lesinurad/allopurinol (trade name Duzallo) is a fixed-dose combination drug for the treatment of gout. It contains 200 mg of lesinurad and 300 mg of allopurinol. In August 2017, the US Food and Drug Administration approved it for the treatment of hyperuricemia associated with gout in patients for whom target serum uric acid levels have not been achieved with allopurinol alone.[1] It was approved for medical use in the European Union in August 2018.[2] In February 2019, it was discontinued by its manufacturer for business reasons and is no longer available.[3][4][2]

References[edit]

  1. ^ "FDA Clears First Fixed-Dose Combination Treatment for Gout". Medscape. August 21, 2017.
  2. ^ a b "Duzallo EPAR". European Medicines Agency (EMA). Retrieved 19 August 2020.
  3. ^ "Duzallo and Zurampic". Ironwood Pharmaceuticals. Retrieved 31 July 2020.
  4. ^ "Withdrawal Zurampic and Duzallo". Grunenthal. 13 January 2019. Retrieved 19 August 2020.